Related Experiment Video
Updated: Mar 23, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
4.4K
Renal denervation for resistant hypertension: no
Stefano Taddei1, Elisa Dal Canto2, Rosa Maria Bruno2
1Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy. stefano.taddei@med.unipi.it.
Internal and Emergency Medicine
|March 23, 2016
Summary
Renal denervation (RDN) for resistant hypertension shows initial promise but lacks confirmed superiority over conventional treatments. Current evidence suggests RDN should not be routine, reserved only for severe, treatment-resistant cases.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Nephrology
Background:
- Resistant hypertension poses a significant clinical challenge.
- Catheter-based renal denervation (RDN) emerged as a potential therapeutic option.
- Initial studies suggested significant blood pressure reduction with RDN.
Purpose of the Study:
- To evaluate the efficacy and current standing of renal denervation for resistant hypertension.
- To compare RDN outcomes with conventional treatments and pharmacological approaches.
- To determine the appropriate clinical role for RDN in managing refractory hypertension.
Main Methods:
- Review of non-randomized and randomized controlled trials.
- Analysis of data from large international registries.
- Assessment of evidence supporting pharmacological management and patient compliance interventions.
Main Results:
- RDN demonstrated reductions in office blood pressure in early studies.
- Randomized controlled trials and large registries have not confirmed RDN superiority over conventional therapy.
- Pharmacological management, combined with improved patient compliance, appears equally or more effective.
Conclusions:
- Based on current evidence, renal denervation should not be routinely employed for resistant hypertension.
- The effectiveness of RDN in specific patient subsets remains unproven.
- RDN use should be restricted to extreme cases where all other treatments have failed.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.8K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
3.0K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
01:23Antihypertensive Drugs: Vasodilators
2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.8K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.8K